Organon and Forendo Pharma announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company...
FOR-6219 was found to be safe and well tolerated by healthy pre- and postmenopausal women and did not induce systemic oestrogen deficiency-related side effects.
Forendo Pharma has received clinical trial authorization (CTA) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to commence a study for its lead program FOR-6219.